Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29564439 | 1.00 | MEN1 (0.44) | MEN1KMT2AKDM1AMAPTMAPK1 | |
| SCHEMBL31473340 | 0.83 | MEN1 (0.41) | MEN1KMT2AKDM1AMAPTMAPK1 | |
| SCHEMBL31166845 | 0.83 | RAB9A (0.49) | KDM1AMAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL416139 | 0.83 | KDM1A (0.48) | KDM1AMAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL27090061 | 0.82 | KDM1A (0.43) | KDM1AMAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL29025569 | 0.82 | KMT2A (0.61) | MEN1KMT2AMAPTTDP1L3MBTL1 | |
| SCHEMBL21835660 | 0.82 | MAPT (0.49) | KDM1AMAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL27262835 | 0.81 | PTPN1 (0.47) | MEN1KMT2AKDM1AMAPK1NPC1 | |
| SCHEMBL27281431 | 0.81 | FFAR4 (0.48) | MEN1KMT2AMAPTMAPK1TDP1 | |
| SCHEMBL18787255 | 0.80 | NPC1 (0.43) | KDM1AMAPTMAPK1TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-221358606-U | Crystallization device for preparing 1-benzyloxy-4-bromo-5-ethyl-2-fluorobenzene | 苏州楚凯药业有限公司 | 2024-07-19 | — | — | CN | claimed |
| CN-114181055-A | Preparation method of 1-benzyloxy-4-bromo-5-ethyl-2-fluorobenzene | 苏州楚凯药业有限公司 | 2022-03-15 | — | — | CN | claimed |
| EP-4359402-B1 | IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12398135-B2 | Dimethyl amino azetidine amides as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-08-26 | — | — | US | disclosed |
| US-12384761-B2 | Imidazolo indazole compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4186908-B1 | JAK INHIBITOR COMPOUND AND USE THEREOF | HENAN MEDINNO PHARMACEUTICAL TECH CO LTD (CN) | 2025-05-07 | — | — | EP | disclosed |
| US-20250034131-A1 | DIMETHYL AMINO AZETIDINE AMIDES AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2025-01-30 | — | — | US | disclosed |
| EP-4114836-B1 | CRYSTALLINE HYDRATE OF A JAK INHIBITOR COMPOUND | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2025-01-08 | — | — | EP | disclosed |
| US-12122773-B2 | Crystalline hydrate of a JAK inhibitor compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-10-22 | — | — | US | disclosed |
| CN-221358606-U | Crystallization device for preparing 1-benzyloxy-4-bromo-5-ethyl-2-fluorobenzene | 苏州楚凯药业有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-221358606-U | Crystallization device for preparing 1-benzyloxy-4-bromo-5-ethyl-2-fluorobenzene | 苏州楚凯药业有限公司 | 2024-07-19 | — | — | CN | disclosed |
| WO-2017079205-A1 | JAK KINASE INHIBITOR COMPOUNDS FOR TREATMENT OF RESPIRATORY DISEASE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-05-11 | — | — | WO | disclosed |
| WO-2017079205-A1 | JAK KINASE INHIBITOR COMPOUNDS FOR TREATMENT OF RESPIRATORY DISEASE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-05-11 | — | — | WO | disclosed |
| US-20170121327-A1 | JAK Kinase Inhibitor Compounds for Treatment of Respiratory Disease | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121327-A1 | JAK Kinase Inhibitor Compounds for Treatment of Respiratory Disease | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-05-04 | — | — | US | disclosed |
| EP-3143021-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | Pfizer Inc (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20170071946-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-9518052-B2 | Pyrazolopyridines and pyrazolopyrimidines | PFIZER INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20150329542-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER INC. | 2015-11-19 | — | — | US | disclosed |
| WO-2015173683-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER INC. (US) | 2015-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034131-A1 | DIMETHYL AMINO AZETIDINE AMIDES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | MEN1 1249/4885KMT2A 70/4885KDM1A 43/4885 |
| US-12398135-B2 | Dimethyl amino azetidine amides as JAK inhibitors | JAK1, JAK2, JAK3 | MEN1 1249/4885KMT2A 70/4885KDM1A 43/4885 |
| US-12122773-B2 | Crystalline hydrate of a JAK inhibitor compound | JAK1, JAK2, JAK3 | MEN1 2986/4885KMT2A 856/4885KDM1A 339/4885 |
| US-20150329542-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | HRH2, HRH4, HRH1 | MEN1 1679/4885KMT2A 3621/4885KDM1A 4398/4885 |
| US-12384761-B2 | Imidazolo indazole compounds as JAK inhibitors | JAK1, JAK3, JAK2 | MEN1 4052/4885KMT2A 1401/4885KDM1A 504/4885 |
| US-20170121327-A1 | JAK Kinase Inhibitor Compounds for Treatment of Respiratory Disease | JAK1, JAK2, JAK3 | MEN1 3430/4885KMT2A 878/4885KDM1A 473/4885 |
| US-20170071946-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | HRH2, HRH4, HRH1 | MEN1 1679/4885KMT2A 3621/4885KDM1A 4398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.